Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region

https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.090

Full Text:

Abstract

Objective: To study the evolution of consumption of antithrombotic drugs used for the treatment of atrial fibrillation (AF) at the outpatient stage in the Saratov Region using the ATC/DDD (Anatomical Therapeutic Chemical Classification / Defined Daily Doses) and drug utilization 90% (DU90%) analysis.
Material and methods. We analyzed the outpatient stage of treatment using the data reflected in 511 case histories of AF patients hospitalized in specialized cardiology departments of the Saratov Region in 2011–2018. The study of the consumption volumes of antithrombotic drugs was carried out using the ATC/DDD- and DU90%-analysis methodology. The consumption of drugs with proven efficacy in AF was expressed as the number of daily doses (NDDD) per 1000 AF patients per day.
Results. In 2011, the number of prescribed DDD of oral anticoagulants (OACs) was 5.29 NDDD per 1000 AF patients per day, and all of them were represented by warfarin; in 2018, this indicator increased up to 277.51 NDDD per 1000 AF patients per day, of which direct OACs amounted to 237.06. The consumption of antiplatelet agents remained at a high level, and in 2018, was 582.53 NDDD per 1000 AF patients per day. Acetylsalicylic acid was included in the group of drugs accounting for 90% of all antithrombotic drugs at the outpatient stage – 99.02% in 2011, 93.08% in 2012, 58.55% in 2016, 60.27% in 2017, and 46.66% in 2018.
Conclusion. The consumption volumes of OACs used at the outpatient stage of treatment of AF in the Saratov Region increased significantly in the period from 2011 to 2018, mainly due to direct OACs. At the same time, the consumption volumes of antiplatelet agents remained at a high level.

About the Authors

А. V. Sokolov
Saratov State Medical University named after V.I. Razumovsky
Russian Federation

Alexey V. Sokolov – Assistant Professor, Chair of Pharmacology

RSCI SPIN-code: 7822-8424 

112 Bolshaya Kazachya Str., Saratov 410012



О. V. Reshet’ko
Saratov State Medical University named after V.I. Razumovsky
Russian Federation

Olga V. Reshet’ko – Dr. Med. Sc., Professor, Chief of Chair of Pharmacology

WoS ResearcherID: I-7011-2013

Scopus Author ID: 36141145800

RSCI SPIN-code: 7569-7915 

112 Bolshaya Kazachya Str., Saratov 410012



References

1. Björck S., Palaszewski B., Friberg L., Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013; 44 (1): 3103–8. https://doi.org/10.1161/STROKEAHA.113.002329.

2. Haim M., Hoshen M., Reges O., et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015; 4 (1): e001486. https://doi.org/10.1161/JAHA.114.001486.

3. Krijthe B.P., Kunst A., Benjamin E.J., et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013; 34 (35): 2746–51. https://doi.org/10.1093/eurheartj/eht280.

4. Conen D. Epidemiology of atrial fibrillation. Eur Heart J. 2018; 39 (16): 1323–4. https://doi.org/10.1093/eurheartj/ehy171.

5. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developedin collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50 (5): e1–88. https://doi.org/10.1093/ejcts/ezw313.

6. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation. 2010; 121 (7): e46–215. https://doi.org/10.1161/CIRCULATIONAHA.109.192667.

7. Wang G., Joo H., Tong X., George M.G. Hospital costs associated with atrial fibrillation for patients with ischemic stroke aged 18–64 years in the United States. Stroke. 2015; 46 (5): 1314–20. https://doi.org/10.1161/STROKEAHA.114.008563.

8. Fuster V., Rydén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2006; 48 (4): 854–906. https://doi.org/10.1016/j.jacc.2006.07.009.

9. Bockeria L.А., Revishvili А.Sh., Oganov R.G., et al. Clinical guidelines on diagnostics and treatment of patients with atrial fibrillation. Journal of Arrhythmology. 2010; 59: 53–77 (in Russ.).

10. Steffel J., Verhamme P., Potpara T.S., et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39 (16): 1330–93. https://doi.org/10.1093/eurheartj/ehy136.

11. Sulimov V.А., Golitsyn S.P., Panchenko Е.P., et al. Diagnosis and treatment of atrial fibrillation. Guidelines of Russian Society of Cardiology, All-Russian Scientific Society of Arrhythmologists and Association of Cardiovascular Surgeons of Russia. Availavle at: https://scardio.ru/content/Guidelines/FP_rkj_13.pdf (in Russ.) (accessed 17.03.2021).

12. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33 (21): 2719–47. https://doi.org/10.1093/eurheartj/ehs253.

13. Arakelyan М.G., Bockeria L.А., Vasilieva Е.Yu., et al. 2020 Clinical guidelines for atrial fibrillation and atrial flutter. Available at: http://webmed.irkutsk.ru/doc/pdf/af.pdf (accessed 17.03.2021).

14. Proietti M., Laroche C., Nieuwlaat R., et al. Increased burden of comorbidities and risk of cardiovascular death in atrial fibrillation patients in Europe over ten years: a comparison between EORP-AF pilot and EHS-AF registries. Eur J Intern Med. 2018; 55: 28–34. https://doi.org/10.1016/j.ejim.2018.05.016.

15. Gadsbøll K., Staerk L., Fosbøl E.L., et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017; 38 (12): 899–906. https://doi.org/10.1093/eurheartj/ehw658.

16. Cowan J.C., Wu J., Hall M., et al. A 10 year study of hospitalized atrial fibrillation-related stroke in England and its association with uptake of oral anticoagulation. Eur Heart J. 2018; 39 (32): 2975–83. https://doi.org/10.1093/eurheartj/ehy411.

17. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009; 361 (12): 1139–51. https://doi.org/10.1056/NEJMoa0905561.

18. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Available at: https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/ (accessed 23.03.2021).

19. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011; 365 (11): 981–92. https://doi.org/10.1056/NEJMoa1107039.

20. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011; 365 (10): 883–91. https://doi.org/10.1056/NEJMoa1009638.

21. Guelker J.E., Bufe A., Klues H., et al. Trends in atrial fibrillation and prescription of oral anticoagulants and embolic strokes in Germany. Cardiovasc Revasc Med. 2019; 20 (5): 399–402. https://doi.org/10.1016/j.carrev.2018.07.019.

22. Sepúlveda R.L., Anaya-Ordóñez S., García E.E., et al. DI-023 Utilisation study of oral anticoagulants (2008–2015) and bleeding due to anticoagulant treatment (2012–2015). Eur J Hosp Pharm. 2017; 24 (Suppl. 1): A122–3. https://doi.org/10.1136/ejhpharm-2017-000640.270.


Review

For citations:


Sokolov А.V., Reshet’ko О.V. Analysis of the consumption volumes of antithrombotic drugs used for pharmacotherapy of atrial fibrillation in Saratov Region. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(4):462-467. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.090

Views: 315


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)